Sotatercept + Background PAH Therapy
Phase 2Completed 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Pulmonary Arterial Hypertension
Conditions
Pulmonary Arterial Hypertension
Trial Timeline
Nov 14, 2024 → Nov 20, 2025
NCT ID
NCT06664801About Sotatercept + Background PAH Therapy
Sotatercept + Background PAH Therapy is a phase 2 stage product being developed by Merck for Pulmonary Arterial Hypertension. The current trial status is completed. This product is registered under clinical trial identifier NCT06664801. Target conditions include Pulmonary Arterial Hypertension.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06925750 | Phase 2 | Active |
| NCT06664801 | Phase 2 | Completed |
Competing Products
20 competing products in Pulmonary Arterial Hypertension